Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
 shares announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, March 14, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain purchasers of shares of Omega Protein Corporation (NYSE:OME) over alleged Securities Laws Violations by Omega Protein Corporation.
Investors, who purchased shares of Omega Protein Corporation (NYSE:OME), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects, including: that Omega Protein’s subsidiary was potentially not in compliance with its probation terms, that the Company was not properly protecting whistleblower employees, that, as a result of the foregoing, the Company was vulnerable to an SEC investigation and potential civil and criminal liability, and that, as a result of the foregoing, Defendants’ statements about Omega Protein’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On March 1, 2017, Omega Protein Corporation disclosed that in December 2016 it had received a subpoena from the Securities and Exchange Commission (“SEC”) seeking information in connection with an investigation of an Omega Protein Corporation subsidiary’s compliance with its probation terms and the Company’s protection of whistleblower employees.
Those who purchased Omega Protein Corporation (NYSE: OME) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
